

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LEE et al

Appl. No.: 10/567,381 (National Phase of PCT/US2004/002702)

I.A. Filed: January 30, 2004

For: Nogo Receptor Antagonists

Confirmation No.: 9649 Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 2159.0430002/EJH/SAC

Second Supplemental Information Disclosure Statement Filing under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450

Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form, PTO/SB/08A are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on July 14, 2006 in connection with the above-captioned application.

In accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents US29-US31, cited on the attached Form PTO/SB/08A are not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is

10567381 - GAU: 1646

- 2 -

LEE et al. Appl. No. 10/567,381

(National Phase of PCT/US2004/002702)

not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return copies of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

- 3 -

LEE et al. Appl. No. 10/567,381 (National Phase of PCT/US2004/002702)

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Shannon A. Carroll, Ph.D. Attorney for Applicants Registration No. 58,240

Date: <u>(lugust 23, 2006</u>

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

572329_1.DOC

AUG 23 2006

Equivalent of Form PTO'SBAA (07.45)
Approved for use through 073/12050
U.S. Pelent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a cathection of information unless st contains a vaid OME control pro-

substitute for form 1449/PTO			0	Complete if Known		
SECO	ND S	UPPL	EMENTAL	Application Number	10/567,381 (National Phase of PCT/US2004/002702)	
INFOR	MA	TION	DISCLOSURE	I.A. Filing Date	January 30, 2004	
STATE	ME	NT RX	APPLICANT	First Named Inventor	Lee, Daniel H.S.	
			ets as necessary)	Art Unit	To be assigned	
				Examiner Name	To be assigned Sandra	
Sheet	1	of	1	Attorney Docket Number	2159.0430002/EJH/SAC	

			U.S. PATENT DOCUMEN	NTS
Examiner Initials	Cite No.1	Document Number Number-Kind Code ^{2 (IFKnown)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	US29	2003/0113325 A1	06/19/2003	Hu et al.
	US30	2003/0113326 A1	06/19/2003	Hu et al.
	US31	2004/0029169 A1	02/12/2004	Hu et al.
	-			

		FOREIGN PATENT DOCU	MENTS	
Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or	-
	Country Code* Number* Kind Code* (if known)	MM-DD-YYYY	Applicant of Cited Document	
		Cite Foreign Patent Document No.	Cite Foreign Patent Document Publication Date	No. Publication Date Name of Patentee or

572341_1.DOC

Examiner Signature /Sandra Wegerl/	Date Considered 11/04/2010
---------------------------------------	----------------------------------------------

"EXAMINET: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not nondermance and not considered. Include copy of this form with next communication to applicant. Applicants ruising catalant designation number (policinal), editing 5 class of USPTO Patient Documents at www.uspto.gov.or MPEP 901.04 - Enter Office that issued the document, by the two-letter code (MPD Standard ST.3) - Ender Office that issued the document, by the two-letter code (MPD Standard ST.3) - Ender Office that issued the document by the appropriate symbols as indicated on the year of the reign of the Emporor must proceed the senial number of the patient document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. "Applicant is to place a check mark here if English processor Transition is attacked."

This collection of information is required by 37 CFR 197 and 198. The information is required to obtain or retain a benefit by the public which is to fise (and by the USFIC) to process) an applicablion. Confidentality is governed by \$8. U.S. C. 122 and 37 CFR 1.1 This collection is estimated to leak 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USFIC). Time will vary depose into look point of the complete day comments on the amount of time you require to complete this form and/or suggestions for reducing this burdon, should be set to Christ Information Officer, U.S. Patient and Trademark Office, P.O. Box .1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissional ref Patients, P.O. Box .1450, Alexandria, VA 22313-1450.